Plus Therapeutics (NASDAQ:PSTV – Get Free Report) and Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.
Profitability
This table compares Plus Therapeutics and Tandem Diabetes Care’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Plus Therapeutics | -193.49% | -805.57% | -105.85% |
| Tandem Diabetes Care | -18.37% | -34.38% | -10.91% |
Earnings & Valuation
This table compares Plus Therapeutics and Tandem Diabetes Care’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Plus Therapeutics | $4.91 million | 1.71 | -$13.32 million | ($3.04) | -0.48 |
| Tandem Diabetes Care | $747.72 million | 3.51 | -$222.61 million | ($2.17) | -18.73 |
Insider & Institutional Ownership
3.3% of Plus Therapeutics shares are owned by institutional investors. 2.3% of Plus Therapeutics shares are owned by insiders. Comparatively, 2.2% of Tandem Diabetes Care shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and target prices for Plus Therapeutics and Tandem Diabetes Care, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Plus Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Tandem Diabetes Care | 0 | 1 | 12 | 0 | 2.92 |
Plus Therapeutics currently has a consensus price target of $8.00, suggesting a potential upside of 444.22%. Tandem Diabetes Care has a consensus price target of $51.25, suggesting a potential upside of 26.11%. Given Plus Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Tandem Diabetes Care.
Volatility & Risk
Plus Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.
Summary
Tandem Diabetes Care beats Plus Therapeutics on 8 of the 13 factors compared between the two stocks.
About Plus Therapeutics
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
